Drug insight: appetite suppressants

被引:24
作者
Bray, GA [1 ]
机构
[1] Louisiana State Univ, Pennington Biomed Res Ctr, Div Clin Obes & Metabl, Baton Rouge, LA 70808 USA
来源
NATURE CLINICAL PRACTICE GASTROENTEROLOGY & HEPATOLOGY | 2005年 / 2卷 / 02期
关键词
appetite suppressant; cannabinoid receptor antagonists; monoamine reuptake; sibutramine; sympathomimetic drug;
D O I
10.1038/ncpgasthep0092
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The term 'appetite suppressant' is used to denote drugs that act primarily on the neurochemical transmitters of the central nervous system to reduce food intake. In addition to drugs that release or mimic the effect of norepinephrine (noradrenaline), this could include drugs that inhibit: reuptake of norepinephrine or 5-hydroxytryptamine (also known as serotonin); bind to the gamma-aminobutyric acid receptors or the cannabinoid receptors; and some peptides that reduce food intake. The sympathomimetic drugs phentermine, diethylpropion, benzphetamine, and phendimetrazine-so named because they mimic many effects of norepinephrine-are only approved in a few countries, and then only for short-term use. Sibutramine, a norepinephrine-5-hydroxytryptamine reuptake inhibitor, is approved for long-term use. Several new mechanisms for drug action are under investigation. Appetite suppressants should be viewed as useful adjuncts to diet and physical activity and might help selected patients to achieve and maintain weight loss.
引用
收藏
页码:89 / 95
页数:7
相关论文
共 43 条
[1]   Bupropion SR enhances weight loss: A 48-week double-blind, placebo-controlled trial [J].
Anderson, JW ;
Greenway, FL ;
Fujioka, K ;
Gadde, KM ;
McKenney, J ;
O'Neil, PM .
OBESITY RESEARCH, 2002, 10 (07) :633-641
[2]  
ASCHER JA, 1995, J CLIN PSYCHIAT, V56, P395
[3]   Sibutramine produces dose-related weight loss [J].
Bray, GA ;
Blackburn, GL ;
Ferguson, JM ;
Greenway, FL ;
Jain, AK ;
Mendel, CM ;
Mendels, J ;
Ryan, DH ;
Schwartz, SL ;
Scheinbaum, ML ;
Seaton, TB .
OBESITY RESEARCH, 1999, 7 (02) :189-198
[4]   Current and potential drugs for treatment of obesity [J].
Bray, GA ;
Greenway, FL .
ENDOCRINE REVIEWS, 1999, 20 (06) :805-875
[5]   A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity [J].
Bray, GA ;
Hollander, P ;
Klein, S ;
Kushner, R ;
Levy, B ;
Fitchet, M ;
Perry, BH .
OBESITY RESEARCH, 2003, 11 (06) :722-733
[6]   Medicinal strategies in the treatment of obesity [J].
Bray, GA ;
Tartaglia, LA .
NATURE, 2000, 404 (6778) :672-677
[7]   Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497
[8]   SR141716, a central cannabinoid (CB1) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats [J].
Cohen, C ;
Perrault, G ;
Voltz, C ;
Steinberg, R ;
Soubrié, P .
BEHAVIOURAL PHARMACOLOGY, 2002, 13 (5-6) :451-463
[9]   Valvular heart disease associated with fenfluramine-phentermine [J].
Connolly, HM ;
Crary, JL ;
McGoon, MD ;
Hensrud, DD ;
Edwards, BS ;
Edwards, WD ;
Schaff, HV .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (09) :581-588
[10]   EVIDENCE AGAINST EITHER A PREMATURE STOP CODON OR THE ABSENCE OF OBESE GENE MESSENGER-RNA IN HUMAN OBESITY [J].
CONSIDINE, RV ;
CONSIDINE, EL ;
WILLIAMS, CJ ;
NYCE, MR ;
MAGOSIN, SA ;
BAUER, TL ;
ROSATO, EL ;
COLBERG, J ;
CARO, JF .
JOURNAL OF CLINICAL INVESTIGATION, 1995, 95 (06) :2986-2988